Forward Ventures ic a venture capital company that focuses in companies in the area of biological sciences.
Business Model:
Revenue: $18.6M
Employees: 11-50
Address: 9255 Towne Centre Drive Suite 350San
City:
State: CA
Zip: 92121
Country: US
Forward Ventures, founded in 1993, is a leading life-science venture capital firm located in San Diego. Forward has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has invested in over 50 companies since it was founded in 1993 and currently has more than $500 million in capital under management. The most recent fund, Forward V, continues Forward Ventures’ program of life sciences and health care venture investing in companies of all stages of development. Forward invests throughout the United States and will consider select European opportunities.
Contact Phone:
+18586776077
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2002 | Kemia | Series A | 16.5M |
2/2010 | Altair Therapeutics | Series B | 17M |
12/2000 | Ambit Biosciences | Series B | 18.8M |
10/2007 | Concurrent Thinking | Venture Round | 3.2M |
10/2005 | Nereus Pharmaceuticals | Series D | 0 |
4/2002 | Micromet | Series B | 0 |
8/2007 | Nereus Pharmaceuticals | Series D | 0 |
5/2005 | Ambit Biosciences | Series C | 31M |
11/2007 | Viracta Therapeutics | Series A | 20M |
4/2017 | Viracta Therapeutics | Series B | 0 |
5/2001 | AGY | Series B | 13M |
4/2010 | Viracta Therapeutics | Series B | 12M |
11/2007 | Asteres | Series C | 4M |
9/2005 | TargeGen | Series C | 30M |
1/2007 | Proprius Pharmaceuticals | Series A | 0 |
1/2002 | Gryphon Therapeutics | Series B | 26M |
9/2003 | NovaCardia | Venture Round | 22M |
8/2005 | Adiana | Series D | 23M |
3/2007 | Affinium Pharmaceuticals | Series A | 18M |
1/2005 | Predix Pharmaceuticals | Series C | 0 |
1/2004 | TargeGen | Series B | 30M |
8/2003 | Micromet | Series C | 0 |
5/2002 | TargeGen | Series A | 10M |
2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
1/1995 | Corixa | Series A | 15M |
8/2011 | Affinium Pharmaceuticals | Series B | 0 |
3/2012 | Viracta Therapeutics | Series B | 0 |
8/2006 | Kemia | Series C | 0 |
4/2002 | Dynavax Technologies | Series D | 0 |
11/2003 | Sanarus Medical | Series C | 19.1M |
7/2001 | Sanarus Medical | Series B | 13.8M |
5/2003 | Acorda Therapeutics | Series B | 55.3M |
1/2006 | Tioga Pharmaceuticals | Series A | 24M |
11/2012 | Ambit Biosciences | Venture Round | 0 |
6/2011 | Ambit Biosciences | Series D | 0 |
10/2006 | Morphotek | Series D | 0 |
4/2007 | NovaCardia | Series B | 18M |
6/2010 | Nereus Pharmaceuticals | Series E | 0 |
9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
8/2015 | Syndax Pharmaceuticals | Series C | 0 |
11/2007 | Ambit Biosciences | Series D | 49.3M |
3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
9/2007 | Sequel Pharmaceuticals | Series A | 20M |
4/2004 | Imagine Pharmaceuticals | Series A | 3.7M |
3/2004 | Kemia | Series B | 33.5M |
9/2003 | Conforma Therapeutics | Series C | 30M |
4/2007 | Syndax Pharmaceuticals | Series A | 40M |
3/2010 | Syndax Pharmaceuticals | Series A | 9M |
8/2013 | Syndax Pharmaceuticals | Series B | 0 |
4/2005 | NovaCardia | Series A | - |
4/2005 | Sanarus Medical | Series D | 23M |
2/2007 | Sanarus Medical | Series E | 15M |
3/2000 | Variagenics | Funding Round | 19M |
1/2001 | Acorda Therapeutics | Series A | 0 |
12/2005 | Hypnion | Series B | 0 |
2/2004 | Morphotek | Series C | 26M |
8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
9/2004 | Cellective Therapeutics | Series A | 27.5M |
8/2019 | Virtuozo | Seed Round | 0 |
9/2006 | NovaCardia | Series B | 48M |
7/2007 | TargeGen | Series D | 40M |
11/2022 | Xanadu | Series C | 0 |
3/2003 | Hypnion | Series B | 47.5M |
11/2022 | Xanadu | Series C | 0 |
8/2019 | Virtuozo | Seed Round | 0 |
4/2017 | Viracta Therapeutics | Series B | 0 |
8/2015 | Syndax Pharmaceuticals | Series C | 0 |
9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
8/2013 | Syndax Pharmaceuticals | Series B | 0 |
11/2012 | Ambit Biosciences | Venture Round | 0 |
3/2012 | Viracta Therapeutics | Series B | 0 |
8/2011 | Affinium Pharmaceuticals | Series B | 0 |
6/2011 | Ambit Biosciences | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|